Qitan Technology completed a $101 million Series C round to support its commercialized nanopore devices. Takeda was approved to launch Exkivity (mobocertinib) in China.
Asia Deal Watch: Astellas Begins 2023 Signing Rare Disease Tie-Ups With Selecta, Twist informa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from informa.com Daily Mail and Mail on Sunday newspapers.